Form 4: Dexcom CFO Sells Shares Under Pre-Arranged 10b5-1 Plan

Dexcom's EVP and Chief Financial Officer, Jereme M. Sylvain, sold 4,824 shares of common stock for $74.17 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of Dexcom Inc. (DXCM), reported a transaction involving the company's common stock.
• On September 2, 2025, Mr. Sylvain disposed of 4,824 shares of Dexcom common stock at a price of $74.17 per share.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan that Mr. Sylvain adopted on May 27, 2025.
• Following the reported sale, Mr. Sylvain beneficially owns 118,657 shares of Dexcom common stock.
• The beneficial ownership includes 83,328 unvested restricted stock units (RSUs) with various vesting schedules, the latest of which extends through March 8, 2028.

Sentiment

Score: 5

Explanation: The sale of shares by an executive, while reducing their direct stake, was conducted under a pre-arranged 10b5-1 plan. This is generally considered a neutral event as it typically reflects personal financial planning rather than a reaction to new company-specific information, thus having minimal impact on sentiment.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 plan, which indicates the transaction was scheduled in advance and not based on new, non-public information, enhancing transparency and mitigating concerns about opportunistic insider selling.

Negatives

• An executive selling shares, even under a 10b5-1 plan, reduces their direct equity alignment with the company's shareholders.

Future Outlook

NA

Management Comments

• Mr. Sylvain adopted a 10b5-1 Plan on May 27, 2025, to allow for the orderly disposition of shares owned by him.

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in the executive's direct equity ownership, but the pre-planned nature under a 10b5-1 plan mitigates concerns about its implications for the company's future prospects.

Key Dates

Recommendation

The filing reports a routine, pre-scheduled sale of shares by an executive under a 10b5-1 plan. This type of transaction is generally not indicative of new material information about the company's prospects and therefore does not warrant a change in investment recommendation based solely on this filing.

Keywords

Dexcom, DXCM, insider trading, Form 4, stock sale, 10b5-1 plan, executive compensation, Jereme Sylvain, CFO